GSK to acquire US-based biopharma company RAPT Therapeutics via a $2.2 billion deal — Details here

British biopharma major GSK to acquire US-based biopharma company RAPT Therapeutics via a $2.2 billion deal. Here’s what investors need to know about the update, which is expected to close by first quarter of 2026.